Key Specifications Table
| Species Reactivity | Key Applications | Host | Format | Antibody Type |
|---|---|---|---|---|
| H | IH(P) | M | Purified | Monoclonal Antibody |
| Description | |
|---|---|
| Catalogue Number | MABC1120-100UG |
| Description | Anti-PD-L2 Antibody, clone 366C.9E5 |
| Alternate Names |
|
| Background Information | Programmed cell death 1 ligand 2 (UniProt: Q9BQ51; also known as PD-1 ligand 2, PD-L2, PDCD1 ligand 2, Programmed death ligand 2, Butyrophilin B7-DC, B7-DC, CD273) is encoded by the PDCD1LG2 (also known as B7DC, CD273, PDCD1L2, PDL2) gene (Gene ID: 80380) in human. Three isoforms of PD-L2 have been reported that are produced by alternative splicing. Isoforms 1 and 2 are single-pass type I membrane proteins and isoform 3 is a secreted protein. PD-1 and PD-1 ligands 1 and 2 (PD-L1 and PD-L2) are B7:CD28 family members that regulate T cell activation and peripheral tolerance. When engaged together with the TCR, the interaction of PD-1 with its ligands delivers an inhibitory signal to T cell proliferation and cytokine production. While PD-L1 is broadly expressed in hematopoietic and non-hematopoietic cells, PD-L2 expression is highly restricted to antigen presenting cells (APCs), including dendritic cells (DCs) and macrophages. The PD-1 pathway plays a key role in the progressive loss of effector T cell responses during chronic HIV infection. Under some conditions, blockade of this pathway can restore many T cell functions. PD-L2 is initially produced with signal peptide (aa 1-19) that is removed to produce the mature protein that contains a large extracellular region (aa. 20-220), a transmembrane domain (aa 221-241), and a cytoplasmic tail (aa 242-273). |
| Product Information | |
|---|---|
| Format | Purified |
| Presentation | Purified mouse monoclonal antibody IgG1 in buffer containing 0.1 M Tris-Glycine (pH 7.4), 150 mM NaCl with 0.05% sodium azide. |
| Quality Level | MQ100 |
| Applications | |
|---|---|
| Application | Anti-PD-L2, clone 366C.9E5, Cat. No. MABC1120, is a mouse monoclonal antibody that detects Programmed cell death 1 ligand 2 (PD-L2) and has has been tested for use in Immunohistochemistry (Paraffin). |
| Key Applications |
|
| Application Notes | Immunohistochemistry Analysis: A 1:250 dilution from a representative lot detected PD-L2 in human prostate tissue. Immunohistochemistry Analysis: A representative lot detected PD-L2 in Immunohistochemistry applications (Sridharan, V., et. al. (2016). Cancer Immunol Res. 4(8):679-87; Roemer, M.G., et. al. (2016). J Clin Oncol. 34(23):2690-7; Chong, L.C., et. al. (2016). Blood. 128(9):1206-13; Calles, A., et. al. (2015). J Thorac Oncol. 10(12):1726-35). |
| Biological Information | |
|---|---|
| Immunogen | Recombinant protein fragment corresponding to the extracellular domain of human PD-L2 (as an Ig fusion protein). |
| Epitope | extracellular domain |
| Clone | 366C.12.9E5.E10.19.1F8 |
| Concentration | Please refer to lot specific datasheet. |
| Host | Mouse |
| Specificity | Clone 366C.12.9E5.E10.19.1F8 specifically detects PD-L2 in human cells. It targets an epitope within the extracellular domain. |
| Isotype | IgG1κ |
| Species Reactivity |
|
| Species Reactivity Note | Human. |
| Antibody Type | Monoclonal Antibody |
| Entrez Gene Number |
|
| Gene Symbol |
|
| Purification Method | Protein G purified |
| UniProt Number |
|
| Molecular Weight | 30.96 kDa calculated. |
| Product Usage Statements | |
|---|---|
| Quality Assurance | Evaluated by Immunohistochemistry (Paraffin) in human tonsil tissue. Immunohistochemistry Analysis: A 1:250 dilution of this antibody detected PD1-L2 in human tonsil tissue. |
| Usage Statement |
|
| Storage and Shipping Information | |
|---|---|
| Storage Conditions | Stable for 1 year at 2-8°C from date of receipt. |
| Packaging Information | |
|---|---|
| Material Size | 100 μg |